全文获取类型
收费全文 | 1551314篇 |
免费 | 110116篇 |
国内免费 | 3632篇 |
专业分类
耳鼻咽喉 | 20287篇 |
儿科学 | 50566篇 |
妇产科学 | 43759篇 |
基础医学 | 217521篇 |
口腔科学 | 43881篇 |
临床医学 | 135908篇 |
内科学 | 313427篇 |
皮肤病学 | 36424篇 |
神经病学 | 127855篇 |
特种医学 | 57879篇 |
外国民族医学 | 484篇 |
外科学 | 226246篇 |
综合类 | 33864篇 |
现状与发展 | 4篇 |
一般理论 | 536篇 |
预防医学 | 123962篇 |
眼科学 | 34044篇 |
药学 | 106247篇 |
41篇 | |
中国医学 | 3883篇 |
肿瘤学 | 88244篇 |
出版年
2021年 | 14084篇 |
2019年 | 14905篇 |
2018年 | 20367篇 |
2017年 | 15481篇 |
2016年 | 16855篇 |
2015年 | 19064篇 |
2014年 | 26752篇 |
2013年 | 38698篇 |
2012年 | 53601篇 |
2011年 | 56545篇 |
2010年 | 32535篇 |
2009年 | 30912篇 |
2008年 | 50958篇 |
2007年 | 53852篇 |
2006年 | 53820篇 |
2005年 | 52669篇 |
2004年 | 50182篇 |
2003年 | 47569篇 |
2002年 | 44413篇 |
2001年 | 75993篇 |
2000年 | 77528篇 |
1999年 | 64257篇 |
1998年 | 18080篇 |
1997年 | 16333篇 |
1996年 | 16468篇 |
1995年 | 15539篇 |
1994年 | 14149篇 |
1993年 | 13281篇 |
1992年 | 47535篇 |
1991年 | 45094篇 |
1990年 | 42995篇 |
1989年 | 41039篇 |
1988年 | 37584篇 |
1987年 | 36690篇 |
1986年 | 34138篇 |
1985年 | 32483篇 |
1984年 | 24707篇 |
1983年 | 20739篇 |
1982年 | 12602篇 |
1981年 | 11176篇 |
1979年 | 21351篇 |
1978年 | 15019篇 |
1977年 | 12439篇 |
1976年 | 11662篇 |
1975年 | 12019篇 |
1974年 | 14412篇 |
1973年 | 13936篇 |
1972年 | 12974篇 |
1971年 | 11766篇 |
1970年 | 11257篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Kamila Pires de Carvalho Mariana Tavares Miranda Lima Fernanda Silva Mazzutti Isis Danyelle Dias Custódio Paula Philbert Lajolo Canto Carlos Eduardo Paiva Yara Cristina de Paiva Maia 《Clinical breast cancer》2019,19(1):e208-e219
Purpose
To study the use of functional capacity (FC) level and duration of aromatase inhibitor (AI) therapy with adiposity parameters in women with breast cancer.Patients and Methods
FC was evaluated through the Health Assessment Questionnaire, which was assessed by classification and divided into 3 groups: G1 = mild to moderate difficulty, G2 = moderate to severe disability, and G3 = severe or very severe disability. Body mass, height, and waist circumference (WC) were measured, and body mass index (BMI) was calculated. Bioelectrical impedance analysis was used to calculate body fat (BF) and fat-free mass. The women were divided into 2 time groups (T1 and T2), which were determined by the median months of AI use (T1 ≤ 29.5 and T2 > 29.5 months).Results
Impaired FC and adiposity parameters were significantly positively correlated. In addition, physical exercise was significantly lower in women assessed as G2 and G3 compared to those assessed as G1. The effect of FC on BMI, BF, and WC was also verified, as was the effect of the duration of AI receipt on BMI and BF. Women at T1 had significantly greater functional disability, BMI, and BF values. In addition, although not statistically significant, women in T1 who were assessed as G3 presented higher BMI, WC, and BF values than those in T2.Conclusion
Adiposity above the recommended parameters and impaired FC were associated with the shortest time of receipt of adjuvant endocrine therapy with AI. 相似文献52.
Edward J.A. Harris Steven Kao Brian McCaughan Takashi Nakano Nobuyuki Kondo Rebecca Hyland Anna K. Nowak Nicholas H. de Klerk Fraser J.H. Brims 《Journal of thoracic oncology》2019,14(2):288-293
Introduction
Malignant pleural mesothelioma (MPM) is an uncommon cancer with a poor prognosis and heterogeneous survival. Surgery for MPM is offered in some specialist centers to highly selected patients. A previously described classification and regression tree (CART) model stratified survival in unselected MPM patients using routinely collected clinical data. This study aimed to examine the performance of this CART model on a highly selected surgical population.Methods
Data were collected from subjects undergoing cytoreductive surgery for MPM from specialist centers in Hyõgo, Japan, and Sydney, Australia, between 1991 and 2016. The CART model was applied using the combination of clinical variables to stratify subjects into risk groups (1 through 4); survival characteristics were then compared.Results
Two hundred eighty-nine cases were included (205 from Australia, 84 from Japan). Overall median survival was 34.6 (interquartile range: 17.5–56.1) months; median age was 63.0 (interquartile range: 57.0–67.8) years, and 83.0% (n = 240) were male. There were no clinically meaningful differences between the two cohorts. Survival across the four risk groups was significantly different (p < 0.0001); the model stratified survival well with a Harrell's concordance statistic of 0.62 (95% confidence interval: 0.57–0.66) at 36 months. The group with the longest survival (median, 82.5 months) had: no weight loss, hemoglobin > 153 g/L and serum albumin > 43 g/L at time of referral to the surgical center.Conclusions
Using routinely available clinical variables, the CART model was able to stratify surgical patients into risk groups with statistically different survival characteristics with fair to good performance. Presence of weight loss, anemia, and low albumin should confer caution when considering surgical therapy for MPM. 相似文献53.
Annette E Hay Nicole Mittmann Michael Crump Matthew C Cheung Jessica Sleeth Judy Needham Mike Broekhoven Marina Djurfeldt Lois E Shepherd Ralph M Meyer Bingshu E Chen Joseph L Pater 《Current oncology (Toronto, Ont.)》2021,28(2):1153
In a prospective study, we sought to determine acceptability of linkage of administrative and clinical trial data among Canadian patients and Research Ethics Boards (REBs). The goal is to develop a more harmonized approach to data, with potential to improve clinical trial conduct through enhanced data quality collected at reduced cost and inconvenience for patients. On completion of the original LY.12 randomized clinical trial in lymphoma (), participants were invited to enrol in the Long-term Innovative Follow-up Extension (LIFE) component. Those consenting to do so provided comprehensive identifying information to facilitate linkage with their administrative data. We prospectively designed a global assessment of this innovative approach to clinical trial follow-up including rates of REB approval and patient consent. The pre-specified benchmark for patient acceptability was 80%. Of 16 REBs who reviewed the research protocol, 14 (89%) provided approval; two in Quebec declined due to small patient numbers. Of 140 patients invited to participate, 115 (82%, 95% CI 76 to 88%) from across 9 Canadian provinces provided consent and their full name, date of birth, health insurance number and postal code to facilitate linkage with their administrative data for long-term follow-up. Linkage of clinical trial and administrative data is feasible and acceptable. Further collaborative work including many stakeholders is required to develop an optimized secure approach to research. A more coordinated national approach to health data could facilitate more rapid testing and identification of new effective treatments across multiple jurisdictions and diseases from diabetes to COVID-19. NCT00078949相似文献
54.
Sabin J. Bozso Jeevan Nagendran Michael W.A. Chu Bob Kiaii Ismail El-Hamamsy Maral Ouzounian Jörg Kempfert Christoph Starck Michael C. Moon 《The Annals of thoracic surgery》2021,111(2):463-470
- Download : Download high-res image (134KB)
- Download : Download full-size image
55.
56.
57.
58.
Marin D. E. Pistol G. C. Gras M. Palade M. Taranu I. 《Naunyn-Schmiedeberg's archives of pharmacology》2018,391(10):1147-1156
Naunyn-Schmiedeberg's Archives of Pharmacology - Ochratoxin A (OTA) and aristolochic acid (AA) are toxins that can frequently contaminate cereals and cereals-based products. The present study... 相似文献
59.
Cost‐Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States
下载免费PDF全文
![点击此处可从《Pharmacotherapy》网站下载免费的PDF全文](/ch/ext_images/free.gif)
60.